Dishman Carbogen Amcis Limited is a global pharmaceutical contract development and manufacturing organization (CDMO) that specializes in the development and manufacturing of active pharmaceutical ingredients (APIs), intermediates, and specialized drug products. With over three decades of experience, the company has established itself as a trusted partner for pharmaceutical companies worldwide. The company operates through three key business segments: the Development Solutions segment, the Manufacturing Solutions segment, and the Commercial Solutions segment.
- Dishman Carbogen Amcis Limited reported Total Income for Q4 FY23 of ₹625.31 Crore up from ₹573.36 Crore year on year, a growth of 9%.
- Total Expenses for Q4 FY23 of ₹667.29 Crore up from ₹646.52 Crore year on year, a growth of 3.2%.
- Consolidated Net Loss of ₹70.72 Crore, widens from loss of ₹44.62 Crore in the same quarter of the previous year.